This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended). A composition for topical application of methylphenidate, comprising methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system, wherein said composition ~~comprises no more than about 5 weight % of acid functional monomers and~~ delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.

Claim 2. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 3. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 4. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 5. (Original). The composition according to claim 1, wherein said increase in said methylphenidate plasma concentration is in the range of 0.4 (ng/mL)/hour to 2.5 (ng/mL)/hour.

Claim 6. (Canceled).

Claim 7. (Original). The composition according to claim 1, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 8. (Original). The composition according to claim 1, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 9. (Original). The composition according to claim 1, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 10. (Original). The composition according to claim 1, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 11. (Currently Amended). A composition for topical application of methylphenidate, comprising methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system,

(i) wherein said composition comprises about 10 to 30 wt% methylphenidate, about 30 to 50 wt% acrylic adhesive, and about 30 to 50 wt% silicone adhesive,

(ii) wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate~~, and~~

~~(iii) wherein said composition comprises no more than about 5 weight % of acid functional monomers~~.

Claim 12. (Original). The composition according to claim 11, wherein said increase in said plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 13. (Original). The composition according to claim 11, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 14. (Original). The composition according to claim 11 wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 15. (Canceled).

Claim 16. (Original). The composition according to claim 11, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 17. (Original). The composition according to claim 11, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 18. (Original). The composition according to claim 11, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 19. (Original). The composition according to claim 11, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 20. (Currently Amended). A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering a composition of methylphenidate and a pharmaceutically acceptable adhesive in a flexible, finite system, wherein said composition ~~comprises no more than about 5 weight % of acid functional monomers and~~ delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate.

Claim 21. (Original). The method according to claim 20, wherein the increasing plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 22. (Original). The method according to claim 20, wherein said increase in said methylphenidate plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 23. (Original). The method according to claim 20, wherein said increase in said methylphenidate plasma concentration is in the range of 0.4 (ng/mL)/hour to 2.5 (ng/mL)/hour.

Claim 24. (Canceled).

Claim 25. (Original). The method according to claim 20, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 26. (Original). The method according to claim 20, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 27. (Original). The method according to claim 20, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 28. (Original). The method according to claim 20, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 29. (Currently Amended). A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering a composition of methylphenidate, and a pharmaceutically acceptable adhesive in a flexible, finite system,

(i) wherein said composition comprises about 10 to 30 wt% methylphenidate, about 30 to 50 wt% acrylic adhesive, and about 30 to 50 wt% silicone adhesive,

(ii) wherein said composition delivers methylphenidate in an amount and rate sufficient to increase the methylphenidate plasma concentration of a subject being treated

over a period of about 6-16 hours, followed by a steady decrease in the plasma concentration of methylphenidate~~, and~~

~~(iii) wherein said composition comprises no more than about 5 weight % of acid functional monomers~~.

Claim 30. (Original). The method according to claim 29, wherein the increasing plasma concentration over about 6-16 hours is followed by a steady decrease in the plasma concentration of methylphenidate over a period of at least about 8 hours.

Claim 31. (Original). The method according to claim 29, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 32. (Original). The method according to claim 29, wherein said increasing plasma concentration is in the range of 0.06 (ng/mL)/hour to 6.0 (ng/mL)/hour.

Claim 33. (Canceled).

Claim 34. (Original). The method according to claim 29, wherein said composition is substantially free of ritalinic acid at the time of manufacture.

Claim 35. (Original). The method according to claim 29, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 24 hours.

Claim 36. (Previously Presented). The method according to claim 29, wherein said composition delivers a therapeutically effective amount over a period of time of about 12 to about 18 hours.

Claim 37. (Original). The method according to claim 29, wherein the methylphenidate is delivered at a rate of about at least 5 mg per 24 hours.

Claim 38. (Original). The method according to claim 20, wherein said increase in said methylphenidate plasma concentration occurs over a period of about 6-12 hours.

Claim 39. (New) The composition according to 1, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.

Claim 40. (New) The composition according to claim 11, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.

Claim 41. (New) The method according to claim 20, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.

Claim 42. (New) The method according to claim 29, wherein said composition comprises no more than about 5% weight/weight of acid functional monomers.